Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01700114Terminated

Post-Approval Study of MelaFind

Role: lead

NCT01387581Completed

Does the Aid of MelaFind Affect Clinical Management Decisions

Role: lead

NCT01700101Completed

MelaFind Evaluations for Patients With Multiple Nevi

Role: lead

NCT00434057Phase 3Completed

Evaluation of Pigmented Skin Lesions With MelaFind(R) System

Role: lead

NCT01011153Completed

Survey Study - Sensitivity Comparison Between MelaFind and Physician Group

Role: lead

All 5 trials loaded